SOLUBILIZED APIRASES, METHODS AND APPLICATIONS Russian patent published in 2023 - IPC C12N9/14 

FIELD: biotechnology.

SUBSTANCE: invention is a solubilized human apyrase containing modifications: N-terminal deletion, C-terminal deletion and modification of the central region, where the length of the N-terminal deletion is from 30 to 50 amino acids, the length of the C-terminal deletion is from 20 to 40 amino acids, and the modification of the central region includes a deletion of 10 to 15 consecutive amino acids, where the deletion is a deletion of amino acids 193 to 204 relative to the wild-type CD39 sequence according to SEQ ID NO: 1 and where the modification of the central region includes a point mutation involving one, two, three, four or five point mutations relative to the wild-type CD39 sequence according to SEQ ID NO: 1 selected from the group consisting of K71E, N73Q, V95A, G102D, Y104S, T106S, R113M, L149M, V151A, E173D, T229A, L254M, K258R, W263R, E276D, N292Q, R304G, I319T, N327Q, F365SN N371Q, K405N, Y412F, L424Q, H436D, I437N, F439S, G441D, N457Q, P463S and S469R. The invention also relates to a pharmaceutical composition for the treatment of tissue damage, containing a therapeutically effective dose of apyrase and one or more pharmaceutically acceptable carriers.

EFFECT: invention improves the efficiency of tissue damage treatment.

16 cl, 12 dwg, 35 tbl, 16 ex